Full name
A Phase 2, Randomized, Double-blind, Multi-dose, Dose Finding Study to Evaluate the Safety, Tolerability and Immunogenicity of AFX3772 Compared With PCV13 in Healthy Infants
NCT Number
NCT05412030
Geography
US
Locations
Puerto Rico, United States
Primary Endpoints
- To describe the safety and tolerability profiles of 3 different dose levels of AFX3772 compared with PCV13 with respect to the proportion of participants with AEs. Day 1 through Day 7 post-vaccination
- To describe the safety and tolerability profiles of 3 different dose levels of AFX3772 compared with PCV13 with respect to the proportion of participants with AEs. Day1 through Day 30
- To describe the safety and tolerability profiles of 3 different dose levels of AFX3772 compared with PCV13 with respect to the proportion of participants with AEs. Day 1 through study completion, an average of 13 months
External Link
https://clinicaltrials.gov/study/NCT05412030
Order
1
Disease
Version
Phase
2